The Top 50 Pharmaceutical Companies mentioned by HCPs on X
| Current Quarter Rank | Previous Quarter Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 7135 | 424 | 7 |
| 2 | 2 | Moderna | 5062 | 185 | 6 |
| 3 | 3 | Johnson & Johnson | 2137 | 420 | 0 |
| 4 | 4 | GSK | 1274 | 224 | 13 |
| 5 | 15 | Novavax | 1149 | 61 | 4 |
| 6 | 8 | AstraZeneca | 1129 | 462 | 27 |
| 7 | 7 | Novo Nordisk | 844 | 451 | 65 |
| 8 | 9 | Bayer | 793 | 158 | 2 |
| 9 | 6 | Merck & Co | 758 | 216 | 22 |
| 10 | 16 | Gilead Sciences | 710 | 126 | 28 |
| 11 | 10 | Roche | 702 | 211 | 27 |
| 12 | 5 | Lilly | 683 | 295 | 0 |
| 13 | 11 | AbbVie | 618 | 428 | 73 |
| 14 | 12 | Sanofi | 585 | 239 | 11 |
| 15 | 13 | Abbott | 559 | 496 | 31 |
| 16 | 14 | Novartis | 487 | 232 | 14 |
| 17 | 18 | Amgen | 352 | 195 | 5 |
| 18 | 19 | Otsuka | 350 | 66 | 11 |
| 19 | 21 | Daiichi Sankyo | 259 | 82 | 22 |
| 20 | 17 | Takeda | 254 | 240 | 0 |
| 21 | 28 | Regeneron | 228 | 79 | 5 |
| 22 | 20 | BMS | 188 | 100 | 2 |
| 23 | 23 | Teva | 182 | 76 | 0 |
| 24 | 26 | Boehringer Ingelheim | 164 | 97 | 4 |
| 25 | 27 | Chugai | 149 | 5 | 3 |
| 26 | 24 | Organon | 89 | 6 | 0 |
| 27 | 30 | Astellas | 86 | 51 | 1 |
| 28 | 31 | UCB | 77 | 44 | 8 |
| 29 | 22 | Fresenius | 71 | 19 | 3 |
| 30 | 29 | STADA Arneimittel | 66 | 2 | 0 |
| 31 | 43 | Grifols | 53 | 1 | 0 |
| 32 | 35 | Vertex | 50 | 50 | 5 |
| 33 | 36 | Menarini | 48 | 43 | 1 |
| 34 | 25 | Servier | 45 | 38 | 3 |
| 35 | 33 | Biogen | 44 | 19 | 1 |
| 36 | 32 | Bausch | 41 | 5 | 1 |
| 37 | 34 | Ipsen | 37 | 3 | 0 |
| 38 | 38 | Jazz Pharmaceuticals | 35 | 32 | 4 |
| 38 | 38 | Dr. Reddy's Labratories | 35 | 7 | 0 |
| 40 | 37 | Merck KGaA | 34 | 26 | 9 |
| 41 | 40 | Viatris | 34 | 10 | 0 |
| 42 | 44 | Incyte | 28 | 11 | 0 |
| 43 | 41 | Eisai | 26 | 8 | 1 |
| 44 | 42 | Sun | 23 | 8 | 0 |
| 45 | 45 | CSL | 18 | 14 | 2 |
| 46 | 46 | Jiangsu Hengrui | 1 | 0 | 0 |
| 47 | 48 | Shanghai | 1 | 0 | 0 |
| 48 | 47 | Mitsubishi Chemical Group | 0 | 0 | 0 |
| 49 | 49 | Yunnan Baiyao Group | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
2025 Q2’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five most mentioned pharmaceutical companies by HCPs on X between April and June 2025 were Pfizer, Moderna, Johnson & Johnson, GSK and Novavax. This is the same top five as last quarter, only with Novavax replacing Eli Lilly in the fifth spot.
CREATION.co tracked over 23,000 mentions by almost 7,300 individual HCPs of pharmaceutical companies between April and June this year.
HHS terminates Moderna’s mRNA injection contract
At the end of May, the US Department of Health and Human Service (HHS) notified Moderna that it would be cancelling its funding contract for mRNA bird flu vaccines. The news came within the first months of Robert F. Kennedy’s “controversial” appointment to secretary of the HHS. HCPs posted over 400 times about this issue, with some calling for Kennedy’s impeachment. There were, some HCPs with sceptical views towards vaccinations welcomed this news.
It’s time to talk about the House moving to impeach RFK Jr. His unilateral actions to restrict COVID vaccine access and also cancel the contract with Moderna for mRNA flu vaccines places the health of this country in jeopardy. He’s unfit to be HHS Sec. https://t.co/girBrlaBgM
— Jonathan Reiner (@JReinerMD) May 29, 2025
Shared by 39 HCPs
FDA orders Pfizer & Moderna to expand COVID-19 safety warnings
Also in May, the FDA ordered Pfizer and Moderna to expand their warning labels on COVID-19 vaccines to include the risk of myocarditis and pericarditis, particularly in young males aged 16-25.
🚨 | LO ÚLTIMO: La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha pedido a Pfizer y Moderna que amplíen las advertencias en las etiquetas de sus vacunas contra la COVID-19 para incluir el riesgo de inflamación cardíaca en adolescentes y hombres jóvenes. pic.twitter.com/Ms6u96WFUm
— Alerta Mundial (@AlertaMundoNews) May 21, 2025
Shared by 9 HCPs
Over 200 HCPs posted about this news. Many came from the traditional vaccine-sceptical angle, celebrating this news. Other HCPs challenged this discourse, but the majority reported on the news by sharing articles such as the one above. This is a typical spread of HCP views on any topic, with there being a wide range of views, however, the majority simply shared news to already established online networks.
ASCO 2025 gets HCPs mentioning pharma in the oncology space
ASCO 2025 ran from 30th May – 03 June, and HCPs were active on X, sharing new trial data, and celebrating the advance of oncology science. Over 400 posts from HCPs discussing the congress mentioned pharma. One such example came from the DeLLphi-304 study, which investigated Amgen’s tarlatamab as a second line treatment for small cell lung cancer (SCLC). In one widely shared post from a medical oncologist in Greece involved in the research, he thanked Amgen’s science team for their contributions to the study.
#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :
✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001
✅ improved QoL (dyspnea and cough)
✅ 27% vs 62% G3 TRAEsGrateful to all collaborators, @Amgen science team and above all our pts pic.twitter.com/knM4KuS0wV
— Giannis Mountzios (@g_mountzios) June 2, 2025
Shared by 58 HCPs
Also at ASCO, 19 HCPs shared a post from physician-scientist Bishoy Faltas about the CLONEVO investigator initiated trial (IIT) in the bladder cancer space. He celebrated a number of things; among them the collaboration between industry and academia. Faltas thanked Eli Lilly and smaller precision medicine company Caris Life Sciences for their support towards the trial and sharing the raw data collected for analysis.
Grateful for the opportunity to present our CLONEVO investigator-initiated trial (IIT) in bladder cancer at @ASCO #ASCO2025. Here are some lessons I learned along the way:
Investigator-initiated trials (IITs) are essential. IITs are clinical trials independently designed and led… https://t.co/fAjaMhFIQp
— Dr. Bishoy M. Faltas (@FaltasLab) June 3, 2025
Shared by 19 HCPs
Semaglutide for metabolic liver disease: the next big thing for Novo’s GLP-1
HCPs mentioned Novo Nordisk this quarter in the context of yet another new indication for their GLP-1 drug, semaglutide. US-based internist and obesity expert Michael Albert shared a post reporting breaking data from the Novo Nordisk-sponsored ESSENCE trial which investigated semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH). As well as mentioning Novo Nordisk as the sponsor, Albert called the results “impressive” in this post, which was shared by nearly 50 HCPs. Albert, ranked fourth on CREATION.co’s DOL Finder Obesity platform for peer impact, was able to disseminate this data (along with Novo’s contribution) widely to his peers as a trusted voice.
🚨BREAKING: Semaglutide for MASH: A Step Forward in Metabolic Liver Disease
Phase 3 data just released (NEJM 2025):In 800 patients with biopsy-confirmed MASH and fibrosis stage 2–3, semaglutide 2.4 mg weekly delivered impressive results at 72 weeks (compared to placebo):… pic.twitter.com/zC2yK36i0y
— Michael Albert, MD (@MichaelAlbertMD) May 1, 2025
Shared by 48 HCPs
One notable comment on this post was from a MASH patient who mentioned @novonordisk requesting that they rebrand Wegovy to aid with insurance coverage – a potential unmet need in the patient space identified when tracking HCP conversation.
Monday Night IBD – 09 June
On 09 June, HCPs in the inflammatory bowel disease (IBD) space again connected for a weekly online conversation between peers. Supported this time by AbbVie, Johnson & Johnson and Takeda through educational grants, HCPs posted over 100 times in June about that week’s discussion. It was led by Dr Aline Charabaty and Dr Nayantara Coelho-Prabhu who respectively ranked 1st and 436th for peer impact on CREATION.co’s DOL Finder platform in the IBD space.
📣#GI #CRSurgery Join us now for this convo led by @NayantaraCoelho @DCharabaty
What factors impact the type of ✂️ you recommend for #dysplasia in #IBD
✅Endo 📸 in this post
🗳️Vignette👇🏽& share your 💬 &expertise w usSupport by edu grants @abbvie @JanssenUS @TakedaPharma pic.twitter.com/U6KVAmkcM3
— #MondayNightIBD (@MondayNightIBD) June 9, 2025
Shared by 6 HCPs
Monday Night IBD is a well-received initiative amongst peers within the gastroenterology community, which poses the question: are there other online initiatives which pharmaceutical companies could support to help grow and nurture a thriving community of HCPs online? If you are interested in how to detect and listen for these initiatives, please get in touch.
The strategic importance of deep HCP social listening
Over the last quarter, HCPs celebrated online when pharmaceutical companies reached endpoints to cancer treatment trials, supported initiatives to address the disparity in clinical trial diversity and worked on treatment options that provide more options to patients.
The top shared links by HCPs when mentioning a Top 50 pharma company discussed were all related to the stories discussed above:
- A news article reporting on the FDA’s decision to cancel the Moderna vaccination contracts.
- A link to this year’s Monday Night IBD schedule.
- A link to the ASCO 2025 program website for one of Johnson & Johnson’s phase 1 multiple myeloma trials.
It’s clear that many HCPs rely on social media to discover and share new medical science. As well as being amplifiers and disseminators of new science, their collective and individual voices provide a powerful guide to how physicians think new treatments will shape patient care now and in the future.
By listening to the online voice of healthcare professionals, medicine manufacturers can discover what’s important to physicians on the front lines of patient care, find out whether their messaging about new medicines is resonating, and predict future HCP behaviours.
At CREATION.co, we’ve been tracking the online HCP voice for over a decade, thanks to our specialist technology platform, CREATION Pinpoint. Talk with us about how our insights can inspire your next innovation.
Find out how the conversation is changing in other Top 50 Trackers and new analysis of the online HCP conversation in a variety of topics.
You can also receive these updates and more straight to your inbox by signing up to CREATION.co’s monthly eJournal.
Methodology notes:
-
- In April – June 2025, CREATION Pinpoint® identified 23,743 posts on X (Twitter) from 7,255 individual HCPs mentioning a Top 50 Pharmaceutical company (based on revenue).
- Data for this research was analysed from the online X conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 April – 30 June 2025.
- While not excluding posts from the final numbers, the analysis shifted focus away from any potential mis- and disinformation, instead honing in on scientifically verifiable HCP opinions. Misinformative opinions are mentioned when considered relevant to the story of the article. Constituting over 70% of all HCP mentions, misinformation was identified using this article as a guide.
- Unless otherwise specified, mentions of a company are not limited to its X account(s).
- In some cases, a post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In April – June 2025, 2,148 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.